Truveta – Weekly Recap

Truveta is a health data and analytics company that aggregates de-identified electronic health records to generate real-world evidence for life sciences firms, health systems, payers, and public health agencies. This weekly summary reviews a series of product, research, and partnership updates that collectively underscore Truveta’s push deeper into regulatory-grade real-world evidence, AI-driven analytics, and high-profile industry engagement.

The most significant development was the formal launch of Truveta Live Link, a prospective research platform that allows life sciences companies to securely connect their proprietary device, diagnostic, or therapy data with Truveta’s continuously updated multimodal EHR dataset. Live Link integrates daily refreshed clinical data, de-identification, governance, and secure storage in a single HIPAA- and HITRUST-certified environment. By enabling prospective, longitudinal studies and audit-ready regulatory evidence, the platform is designed to replace fragmented vendor stacks and bespoke registries and to support HEOR, regulatory, commercial, and market access use cases. Truveta’s extensive network of major U.S. health systems underpins the breadth and timeliness of this data asset.

The company quickly showcased Live Link’s capabilities through a collaboration with Dexcom, in which proprietary continuous glucose monitoring data was linked to longitudinal EHR records for more than 200,000 patients. Early analyses found that CGM use was associated with slower progression of chronic kidney disease and a 14% reduction in the rate of kidney function decline. This case study illustrates how the platform can generate high-value, real-world evidence for medical device manufacturers and potentially for pharmaceutical sponsors and regulators.

Truveta also highlighted new research featured in JAMA Network Open and covered by NBC News, examining early childhood vaccination patterns and measles immunization. Using data from more than 320,000 children, the study documented declining on-time MMR vaccination and showed that delays in early infant vaccines significantly increase the likelihood of missing the first MMR dose by age two. The publication reinforces Truveta’s credibility as a source of large-scale, peer-reviewed clinical insights relevant to population health.

In addition, the company used its “Saving Lives with Data” newsletter and participation in a Bain Capital AI event at the JPM Healthcare conference to emphasize its role at the intersection of AI, real-world data, and drug development. Truveta promoted ongoing work in biomedical AI using large language models, research on GLP-1 utilization patterns, and an upcoming webinar on modernizing clinical trial design with real-world data.

Taken together, this week’s developments highlight Truveta’s strategic focus on expanding its real-world evidence platform, demonstrating concrete use cases with industry partners, and building scientific and industry credibility—factors that could support deeper enterprise adoption and longer-term revenue growth if customer uptake continues to scale.